Company intelligence / Profile preview
HiST Pharma
Guangzhou, Chinaclinicaltrialsarena.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
HiST Pharma's TC Cream demonstrated superior efficacy over the vehicle in its Phase IIb clinical study (NCT03372811) under an 8-week regimen, with an excellent safety and tolerability profile. The FDA has approved the initiation of a Phase III clinical trial for TC Cream to treat psoriasis vulgaris.[1][2]
- Therapeutic areas
- Dermatology
- Modalities
- Botanical small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Planning global licensing strategy with biotech pharma partners
Beyond the preview
Go deeper on HiST Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HiST Pharma.